WallStSmart

AbbVie Inc (ABBV)vsCaring Brands, Inc. Common Stock (CABR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 1490367634% more annual revenue ($62.82B vs $4,215). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

CABR

Avoid

13

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 5/9Altman Z: 6.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-20.5%)

Margin of Safety

-20.5%

Fair Value

$168.19

Current Price

$202.71

$34.52 premium

UndervaluedFair: $168.19Overvalued

Intrinsic value data unavailable for CABR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$365.43B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

CABR1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
6.9210/10

Safe zone — low bankruptcy risk

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
100.8x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

CABR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.61M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-217.1%2/10

ROE of -217.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : CABR

The strongest argument for CABR centers on Altman Z-Score.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.

Bear Case : CABR

The primary concerns for CABR are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABBV is growing revenue faster at 12.4% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (63/100 vs 13/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Caring Brands, Inc. Common Stock

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Caring Brands, Inc., a wellness consumer products company, provides over-the-counter and cosmetic consumer products. The company is headquartered in Fort Pierce, Florida.

Want to dig deeper into these stocks?